Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 329481, 10 pages
http://dx.doi.org/10.1155/2015/329481
Review Article

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives

1Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, 69126 Heidelberg, Germany
2Translational Lung Research Center Heidelberg (TLRCH), Member of the German Center for Lung Research (DZL), 69126 Heidelberg, Germany
3Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, 45141 Essen, Germany
4Department of Pulmonary Disease, Erasmus Medical Centre, University Hospital Rotterdam, 3015 CE Rotterdam, Netherlands
5National Institute for Health Research Biological Research Unit, Royal Brompton Hospital, London SW3 6NP, UK
6National Heart and Lung Institute, Imperial College, London SW3 6NP, UK
7Medical University Clinic, Canton Hospital Baselland and University of Basel, 4410 Liestal, Switzerland

Received 4 September 2015; Accepted 11 November 2015

Academic Editor: Natale Daniele Brunetti

Copyright © 2015 Michael Kreuter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [24 citations]

The following is the list of published articles that have cited the current article.

  • Andrea Koch, Philipp Markart, Frank Reichenberger, Michael Westhoff, Martin J. Kohlhaeufl, Antje Prasse, Francesco Bonella, Jürgen Behr, Jürgen Hetzel, Marco Idzko, Peter Kardos, Christian Schumann, Wolfram Windisch, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Joachim Müller-Quernheim, and Katrin Milger, “Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis,” Respiration, vol. 92, no. 2, pp. 98–106, 2016. View at Publisher · View at Google Scholar
  • Adilson Santos Andrade-Sousa, Paulo Rogério Pereira, BreAnne MacKenzie, Manoel Carneiro Oliveira-Junior, Erasmo Assumpção-Neto, Maysa Alves Rodrigues Brandão-Rangel, Nilsa Regina Damaceno-Rodrigues, Elia Garcia Caldini, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Ana Paula Ligeiro de Oliveira, Marisa Dolhnikoff, Oliver Eickelberg, and Rodolfo Paula Vieira, “Aerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice,” Plos One, vol. 11, no. 9, pp. e0163420, 2016. View at Publisher · View at Google Scholar
  • Alan Betensley, Rabab Sharif, and Dimitrios Karamichos, “A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis,” Journal of Clinical Medicine, vol. 6, no. 1, pp. 2, 2016. View at Publisher · View at Google Scholar
  • J. Alberto Neder, Denis E. O’Donnell, Ingrid Harle, and Onofre Moran-Mendoza, “Chronic breathlessness in patients with idiopathic pulmonary fibrosis: a major challenge for caregivers,” Expert Review of Respiratory Medicine, vol. 10, no. 12, pp. 1295–1303, 2016. View at Publisher · View at Google Scholar
  • Birring, Costabel, Bonella, Kreuter, Wijsenbeek, Wapenaar, and Oltmanns, “German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire",” Pneumologie, vol. 70, no. 11, pp. 742–746, 2016. View at Publisher · View at Google Scholar
  • Michael Kreuter, Julia Wälscher, and Jürgen Behr, “Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: The time is now (?),” Current Opinion in Pulmonary Medicine, vol. 23, no. 5, pp. 418–425, 2017. View at Publisher · View at Google Scholar
  • Jing Tang, Dai Li, Jian Ming Li, Guo Li, Hai Tao Zhang, Ling Wang, and Jin Song Ding, “Spermidine-mediated poly(Lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis,” International Journal of Nanomedicine, vol. 12, pp. 6687–6704, 2017. View at Publisher · View at Google Scholar
  • Toby M. Maher, Maria Molina-Molina, Anne-Marie Russell, Stéphane Jouneau, Elena Ripamonti, Judit Axmann, Carlo Vancheri, and Francesco Bonella, “Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries,” BMC Pulmonary Medicine, vol. 17, no. 1, 2017. View at Publisher · View at Google Scholar
  • Martin W. Rowbottom, Gretchen Bain, Imelda Calderon, Taylor Lasof, David Lonergan, Andiliy Lai, Fei Huang, Janice Darlington, Patricia Prodanovich, Angelina M. Santini, Christopher D. King, Lance Goulet, Kristen E. Shannon, Gina L. Ma, Katherine Nguyen, Deidre A. MacKenna, Jilly F. Evans, and John H. Hutchinson, “Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2),” Journal of Medicinal Chemistry, 2017. View at Publisher · View at Google Scholar
  • John H. Hutchinson, Martin W. Rowbottom, David Lonergan, Janice Darlington, Pat Prodanovich, Christopher D. King, Jilly F. Evans, and Gretchen Bain, “Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX,” ACS Medicinal Chemistry Letters, vol. 8, no. 4, pp. 423–427, 2017. View at Publisher · View at Google Scholar
  • Andrew P. Binks, Renee J. LeClair, Megyn Beyer, and Ryan Miller, “Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function,” Physiological Reports, vol. 5, no. 5, 2017. View at Publisher · View at Google Scholar
  • Michael Kreuter, and Vincent Cottin, “The yin and yang of idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 49, no. 2, 2017. View at Publisher · View at Google Scholar
  • Xiang Li, Xiaopei Yan, Yanli Wang, Jingjing Wang, Fang Zhou, Hong Wang, Weiping Xie, and Hui Kong, “NLRP3 Inflammasome Inhibition Attenuates Silica-Induced Epithelial to Mesenchymal Transition (EMT) in Human Bronchial Epithelial Cells,” Experimental Cell Research, 2017. View at Publisher · View at Google Scholar
  • Hangming Dong, Lishan Luo, Mengchen Zou, Chaowen Huang, Xuan Wan, Yahui Hu, Yanqing Le, Haijin Zhao, Wei Li, Fei Zou, and Shaoxi Cai, “Blockade of extracellular heat shock protein 90α by 1G6-D7 attenuates pulmonary fibrosis through inhibiting ERK signaling,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 313, no. 6, pp. L1006–L1015, 2017. View at Publisher · View at Google Scholar
  • Paolo Comeglio, Annamaria Morelli, Luciano Adorini, Mario Maggi, and Linda Vignozzi, “Beneficial effects of bile acid receptor agonists in pulmonary disease models,” Expert Opinion on Investigational Drugs, vol. 26, no. 11, pp. 1215–1228, 2017. View at Publisher · View at Google Scholar
  • Vidhata Rani, Swetlana Gautam, Jitendra K. Rawat, Manjari Singh, Uma Devi, Rajnish K. Yadav, Subhadeep Roy, and Gaurav Kaithwas, “Effects of minocycline and doxycycline against terbutaline induced early postnatal autistic changes in albino rats,” Physiology & Behavior, 2017. View at Publisher · View at Google Scholar
  • Xiaohong Zheng, Si Zhang, Yinshan Fang, Chao Qi, and Wen Ning, “TGF-β1 induces Fstl1 via the Smad3-c-jun pathway in lung fibroblasts,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 313, no. 2, pp. L240–L251, 2017. View at Publisher · View at Google Scholar
  • Jianhong Wang, Wenwen Zhai, Jiaqi Yu, Jie Wang, and Jundong Dai, “Preparation and Quality Evaluation of Salvianolic Acids and Tanshinones Dry Powder Inhalation,” Journal of Pharmaceutical Sciences, 2018. View at Publisher · View at Google Scholar
  • Nicolas Kahn, Anne-Kathrin Rossler, Katrin Hornemann, Thomas Muley, Ekkehard Grünig, Werner Schmidt, Felix J.F. Herth, and Michael Kreuter, “C-proSP-B: A Possible Biomarker for Pulmonary Diseases?,” Respiration, vol. 96, no. 2, pp. 117–126, 2018. View at Publisher · View at Google Scholar
  • Michela Terlizzi, Antonio Molino, Chiara Colarusso, Chantal Donovan, Pasquale Imitazione, Pasquale Somma, Rita P. Aquino, Philip M. Hansbro, Aldo Pinto, and Rosalinda Sorrentino, “Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators,” Frontiers in Immunology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • José Antonio Rodríguez-Portal, “Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update,” Drugs in R and D, vol. 18, no. 1, pp. 19–25, 2018. View at Publisher · View at Google Scholar
  • Kreuter, Prasse, Schreiber, Wälscher, Bonella, Claussen, Jungmann, Nowak, Petermann, Pfeiffer, Polke, Wirtz, Kirsten, Ochmann, Koschel, Behr, Costabel, and Kolb, “DGP Interstitial Lung Disease Patient Questionnaire,” Pneumologie, 2018. View at Publisher · View at Google Scholar
  • Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J.F. Herth, and Michael Kreuter, “Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis,” Respiration, vol. 95, no. 5, pp. 301–309, 2018. View at Publisher · View at Google Scholar
  • Lizzy Peix, Iona C. Evans, David R. Pearce, Juliet K. Simpson, Toby M. Maher, and Robin J. McAnulty, “Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis,” Scientific Reports, vol. 8, no. 1, 2018. View at Publisher · View at Google Scholar